Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Legend interim CEO talks rising competition as Carvykti maker posts first profit
More than four years after its CAR-T star Carvykti’s initial FDA approval, Legend Biotech has reached a major milestone, posting its first profitable quarter. | Legend Biotech's interim CEO Alan Bash discusses competition from T-cell engagers and Gilead's new autologous CAR-T, as the Carvykti maker posted its first profitable quarter.
TL;DRAI
Legend Biotech posted Q2 profitability ($63M) on Carvykti CAR-T; J&J's bispecifics and Gilead's anito-cel raise competition. Myeloma's <10% BCMA penetration and CAR-T-first clinical preference secure runway; J&J partnership and manufacturing offset TCE threats.
1,192 words~5 min read
